Short Interest in Barinthus Biotherapeutics plc (NASDAQ:BRNS) Rises By 134.0%

Barinthus Biotherapeutics plc (NASDAQ:BRNS) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 12,400 shares, a growth of 134.0% from the December 15th total of 5,300 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily volume of 49,800 shares, the short-interest ratio is currently 0.2 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright dropped their target price on Barinthus Biotherapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Monday.

Barinthus Biotherapeutics Stock Performance

BRNS traded up $0.02 during trading on Thursday, reaching $1.04. The stock had a trading volume of 10,442 shares, compared to its average volume of 44,704. The stock has a market cap of $41.64 million, a PE ratio of -0.69 and a beta of -0.81. Barinthus Biotherapeutics has a one year low of $0.80 and a one year high of $4.16. The business has a 50-day moving average of $1.07 and a 200-day moving average of $1.24.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its earnings results on Wednesday, November 6th. The company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.23. The firm had revenue of $14.97 million during the quarter. During the same quarter in the previous year, the company posted ($0.37) earnings per share. Equities research analysts forecast that Barinthus Biotherapeutics will post -1.52 EPS for the current fiscal year.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.